study hypothesis: The purpose of this study was to analyze DPY19L2 sequence variants to investigate the mechanism leading to the entire DPY19L2 deletion in a large cohort of infertile globozoospermic patients. study finding: An improved analysis of the DPY19L2 deletion breakpoints (BPs) allowed us to identify two BPs located in a small 1 kb region and to more precisely localize the BPs reported previously.
Introduction
Approximately 15% of couples worldwide are confronted with infertility and 50% of the cases are attributed to male factors. Most of these cases are believed to have a genetic component (O'Flynn O'Brien et al., 2010) . Recently, several genes involved in each stage of spermatogenesis and linked to different phenotypes of male infertility have been identified. Globozoospermia is one of the rare forms of monomorphic teratozoopsermia (incidence ,0.1%) characterized in its total form by the presence in the ejaculate of 100% or close to 100% round-headed spermatozoa lacking an acrosome. So far, three genes have been described as responsible for this phenotype: spermatogenesis associated 16 (SPATA16), protein interacting with PRKCA 1 (PICK1) and DPY19L2 (Dam et al., 2007; Liu et al., 2010; Harbuz et al., 2011; Koscinski et al., 2011) . In 2007, a homozygous mutation (c.848 G.A) in exon 4 of SPATA16 was identified in three affected brothers from an Ashkenazi Jewish family. However, this mutation was not detected in 29 other globozoospermic patients including 6 familial cases (Dam et al., 2007) . In 2010, a homozygous missense mutation (c.1567 G.A) in exon 13 of PICK1 was identified in a Chinese patient with total globozoospermia and no other PICK1 mutations were identified in two additional unrelated globozoospermic patients (Liu et al., 2010) . More recently, a large homozygous deletion of 200 kb encompassing the entire DPY19L2 locus was detected in a consanguineous Jordanian family (Koscinski et al., 2011) .
The study of Dpy19l2 knockout mice, reproducing the human globozoospermia phenotype, showed that Dpy19l2 is expressed predominantly in spermatids with a very specific localization restricted to the inner nuclear membrane facing the acrosomal vesicle. In the absence of Dpy19l2, the inner nuclear membrane becomes separated from the outer nuclear membrane, leading to the detachment of the acrosome associated with the outer nuclear membrane and therefore to the absence of acrosomes (Pierre et al., 2012) .
It has been shown that DPY19L2 is the major gene responsible for human globozoospermia (Harbuz et al., 2011; Koscinski et al., 2011) . The mechanism underlying the recurrent deletion is a non-allelic homologous recombination (NAHR) event taking place between two highly similar 28 kb low copy repeats (LCRs) flanking the gene (Fig. 1A ) (Harbuz et al., 2011; Koscinski et al., 2011) . Elinati et al. (2012) characterized nine breakpoints (BPs) for the DPY19L2 NAHR-driven deletion defining two recombination hotspots both containing direct repeat elements. Hotspot1 accounts for the majority of DPY19L2 NAHR-driven deletions with seven different BPs (BP1-BP7) clustered in this region. Hotspot 2, a less frequent recombination hotspot, comprises only two BPs (BP8 and BP9) (Elinati et al., 2012) .
Owing to the absence of an acrosome, the round-headed spermatozoa are unable to penetrate the zona pellucida of an oocyte and trigger oocyte activation. Fertilization and pregnancies can be achieved with ICSI; however, the success rates are generally very low (Kilani et al., 2004; Dirican et al., 2008; Banker et al., 2009; Bechoua et al., 2009) . Several studies suggest that the low rate of fertilization in globozoospermic patients is partially caused by a decrease in the level or a defect in the oocyte activation factor, the phospholipase C z, assumed to be the main physiologic factor responsible for oocyte activation (Ikawa et al., 2010; Kashir et al., 2010; Alvarez Sedo et al., 2012) . It was recently shown that ICSI combined with assisted oocyte activation (AOA) overcomes this fertilization failure for both DPY19L2 mutated and non-mutated globozoospermic patients (Kuentz et al., 2013) .
By studying a large cohort of 64 patients including 54 genetically independent globozoospermic patients from different countries (Algeria, France, Iran, Turkey, Italy, Libya, Morocco and Tunisia), 36 (66.7%) were shown to be mutated for DPY19L2 (Elinati et al., 2012) . Coutton et al. (2012) detected a molecular defect in DPY19L2 in 26 out of 31 (84%) patients analyzed, mainly from Tunisia (22 out of 31). Analyzing DPY19L2 among Chinese globozoospermic patients, Zhu et al. (2013) found that 60% (9 out of 15) have a sequence variation in DPY19L2 on both alleles. Noveski et al. (2013) and Ounis et al. (2015) reported a homozygous deletion of the DPY19L2 gene in two Macedonian men and three unrelated Algerian patients, respectively.
The main objective of the present study was to analyze DPY19L2 and to investigate the mechanism leading to the entire DPY19L2 deletion. In order to distinguish between single-nucleotide polymorphisms (SNPs) and LCR-specific markers (SM) and to properly define the localization of the BPs of the DPY19L2 deletion, we sequenced LCR1 and LCR2 in 35 control fertile Tunisian men. This allowed us to precisely delineate BPs in the present cohort of patients, but also to redefine the localization of the BPs reported in our previous study (Elinati et al., 2012) and in another study (Coutton et al., 2013) . Furthermore, we excluded any possibility of a founder effect, even recent, in our cohort confirming again that the deletion results from recurrent events linked to the structural features of the locus (Elinati et al., 2012) .
Materials and Methods

Patients and controls
A total of 21 Tunisian patients were included in this study. Twenty were recruited between June 2009 and May 2015 during routine infertility treatment in the Laboratory of Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Hospital (Sousse, Tunisia) and one was referred to the Institut de Génétique et Biologie Moléculaire et Cellulaire laboratory (Université de Strasbourg, Illkirch, France) for molecular analysis. All patients included were described to have an absolute teratozoospermia (100% abnormal morphology). Additionally, 35 fertile Tunisian men were included as controls. All patients and controls gave their written informed consent. The study was approved by the ethics committee of Farhat Hached University Hospital (Sousse, Tunisia) and by the local Ethics Committee (Comité de Protection de la Personne, CPP) of Strasbourg University Hospital (CPP 09/40-W AC-2008 -438 1W DC-2009 .
Sperm analysis
Routine sperm analyses were carried out in the Laboratory of Cytogenetics, Molecular Genetics and Reproductive Biology. The basic semen parameters were assessed according to the World Health Organization guidelines (WHO, 2010) . Sperm morphology was assessed according to David's modified classification (Auger et al., 2001) . For each patient, at least two consecutive semen analyses were performed within a period of 3 months.
DNA extraction
Genomic DNA was extracted from peripheral blood leukocytes using the FlexiGene DNA Kit (Qiagen, France) according to the manufacturer's instructions.
Deletion screening
The DPY19L2 deletion was detected by performing a PCR of exon 10 and PCRs of three BP fragments, referred to as BPa, BPb and BPc (Fig. 1A) . BPa fragment encompasses six (BP1-BP6) of the nine BPs identified previously by Elinati et al. (2012) , BPb encompasses one BP (BP7) and BPc encompasses two BPs (BP8 and BP9). BPa PCR generates a 1700 bp fragment only in patients carrying the DPY19L2 deletion ( Fig. 1B and C) . BPa PCR products were sequenced in order to characterize the deletion BP regions. For the patients who showed an amplification of exon 10 with a negative result for BPa, PCRs of BPb and BPc were then performed (Fig. 1D) . The primer sequences for exon 10 and for PCRs covering the different BPs (BPa, BPb and BPc) as well as PCR conditions were as described previously (Elinati et al., 2012) .
BP analysis
In order to identify SNPs and LCR1 and LCR2-specific markers, we sequenced a 2 kb fragment on LCR1 and LCR2 in 35 fertile control Tunisian men. Multiple sequence alignment was performed to differentiate between nucleotides that differed between LCR1 and LCR2 using the ClustalW2 program with as query sequences the reference human sequence (Hg19) for both LCR1 and LCR2. Primers used to amplify the 2 kb fragments were as described previously (Coutton et al., 2013) .
Mutation screening
For patients without a DPY19L2 deletion, all 22 exons of DPY19L2 and intron boundaries were amplified using primers described previously (Elinati et al., 2012) . SPATA16 and PICK1 were analyzed in four patients lacking a DPY19L2 mutation. The 11 SPATA16 exons and 13 PICK1 exons and their intron boundaries were amplified as indicated in Supplementary Tables SI  and SII . DPY19L2, SPATA16 and PICK1 amplicons were sequenced by GATC (Cologne, Germany).
Web Resources
LCR alignment was performed using the ClustalW2 program (http:// www.ebi.ac.uk/Tools/msa/clustalw2/). The URLs for bioinformatics Regions designated as 'a, b and c' refer to PCR sequences of the BP fragments, respectively, BPa, BPb and BPc, covering the nine BPs described in our previous study (Elinati et al., 2012 ) (see the Materials and Methods section). Specific primers located in LCR1 and LCR2 for each of the BP fragments amplified (small arrows) were used to amplify the recombined fragment LCR1/LCR2 resulting only in patients carrying the 200 kb DPY19L2 deletion. (B) PCR results of DPY19L2 Exon 10 and BPs. GloboT2, 3, 5 -9, 11 and 14 are deleted for exon10. GloboT1, 4, 13, 15 and 16 and the Fertile Control showed an amplification of the exon. All patients with the deletion showed amplification for BPa (1700 bp fragment). (C) PCR results for GloboT17 and 18 also homozygously deleted for DPY19L2 with BPa amplification. GloboT19 and 21 showed an amplification of exon 10. (D) PCR results of BPb and BPc for GloboT1, 4, 13, 15, 16, 19 and 21 showed amplification only for the control PCRs (two globozoospermic patients proved to be homozygous for the deletion at BPb showing an amplification of 1600 bp fragment and the second control homozygous for the deletion at BPc showing an amplification of 1500 bp fragment). M, size marker. prediction tools used to assess the R298C mutation are as follows: PolyPhen (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi. org/), MutPred (http://mutpred.mutdb.org), MuStab (http://bio info.ggc.org/mustab/), SNPs and GO software (http://snps-and-go. biocomp.unibo.it/snps-and-go/). Exome Variant Server (EVS) database (http://evs.gs.washington.edu/EVS/) and Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org/). Websites: NetGene2 Server (http://www.cbs.dtu.dk/services/NetGene2/), Alternative Splice Site Predictor (http://wangcomputing.com/assp/index. html) and Splice Site Prediction by Neural Network (http://www. fruitfly.org/seq_tools/splice.html) were used to evaluate the effect of the novel mutation identified in exon/intron 16.
Results
Characteristics of the cohort
All 21 patients consulted for primary infertility. They were unrelated except for three pairs of siblings (GloboT-2/GloboT-20, GloboT-9/ GloboT-10 and GloboT-11/GloboT-12). Therefore, we included 18 genetically independent patients in this study; eight of them born of consanguineous marriages (first degree), eight born of non-consanguineous marriages (first or second degree) and no data were available for two patients. The conventional semen parameters for all patients are summarized in Table I . Semen analyses showed that 17 patients displayed complete or almost complete globozoospermia with close to 100% round-headed spermatozoa with no acrosome and four patients displayed partial globozoospermia with 44 -78% round-headed spermatozoa and 75-100% spermatozoa with no acrosome. The mean sperm concentration was in the normal range (75.83 × 10 6 /ml), the average viability was 50.45% and average progressive motility was 12.64% indicating an asthenozoospermia for all patients.
Patients presented a normal karyotype except GloboT-6 who presented a pericentric inversion of the Y chromosome; the conventional karyotype was 46, X inv (Y) (p11q11). No Y chromosome microdeletion was found in any of the patients examined.
DPY19L2 deletion screening
Eleven of 18 genetically independent patients were homozygous for the DPY19L2 deletion. For these patients, no amplification of exon 10 occurred and amplification of a 1700 bp fragment (BPa PCR) was visualized ( Fig. 1B and C) .
Seven patients did not display the DPY19L2 deletion; an amplification of exon 10 was observed and no amplification of the BPa, BPb and BPc fragments was detected, suggesting that none of them were heterozygous for the deletion (Fig. 1D) . We cannot exclude a heterozygous deletion involving a new BP that may lie outside the analyzed PCR fragments BPa, BPb and BPc.
BP localization: LCR-specific markers and SNPs
One major difficulty in defining BP localization stems from the high degree of similarity between LCR1 and LCR2. In order to properly distinguish between SNPs and LCR1 and LCR2-specific markers, we sequenced 2 kb regions on LCR1 and LCR2 in a total of 35 fertile Tunisian controls. Among nucleotides that differed between the two LCRs, 15 invariant nucleotides are specific for each LCR (SM) ( Table II) and were used to map the deletion BPs. Twenty nucleotides were found to be non-LCR-specific and should be considered as SNPs (Table III) . These SNPs were used to establish patient haplotypes. Allelic frequencies of each SM and SNP are reported in Supplementary Tables SIII and SIV. Based on the presence of 15 SM, sequence analysis of the amplification products (BPa PCR: 1700 bp) in patients homozygous for the DPY19L2 deletion revealed two different BPs localized within a small 1 kb region. Two patients (GloboT-2 and 17) had BP1 between specific markers 4 and 5 and nine patients (5) (6) (7) (8) (9) 11, 14 and 18) had BP2 between specific markers 3 and 4 (Table II) .
Twenty SNPs were then used to identify the different haplotypes in patients presenting the same BP. We identified a total of eight distinct haplotypes (Table III) , indicating that at least eight recombination events are at the origin of the DPY19L2 deletion. Two haplotypes (Hap1 and Hap2) were observed for BP1 in patients from different geographic regions and six different haplotypes were identified for BP2 (Hap3-Hap8). Hap3 was found in two patients originating from the same region. Hap5 was shared by three patients from two different areas and four other haplotypes were identified in four patients from two different regions. Altogether, these results strongly support the absence of a founder effect and support the advent of recurrent NAHR events linked to the locus-specific genomic architecture.
In view of this new SM definition, we reanalyzed the previous reports dealing with the DPY19L2 deletion. Rechecking our previous 9 BPs reported in 27 globozoospermic patients homozygously deleted for DPY19L2 with 7 different BPs (BP1 -BP7) clustered in the hotspot 1 region (1.7 kb) and 2 BPs (BP8 and BP9) in hotspot 2 (117 bp) (Elinati et al., 2012) (Fig. 2A) , we found that the nucleotide variants used to define BP1-BP6 were in fact SNPs. Using the new LCR-SM defined in the present study, we conclude that those six BPs (BP1-BP6) correspond to BP2 ( Fig. 2A and C) . Thus, 24 out of the previous 27 patients analyzed had BP2. The remaining three patients had three BPs (BP7, 8 and 9) that fell outside the region studied.
Screening DPY19L2, SPATA16 and PICK1 genes
For the seven patients without a DPY19L2 deletion, we sequenced each of the 22 DPY19L2 exons and exon-intron boundaries. Two patients from non-consanguineous marriages (first or second degree) were found to be homozygous for the non-synonymous mutation (c.892C.T) in exon 8 previously identified (Elinati et al., 2012) . This mutation (p.R298C) entails the substitution of a strictly conserved Arginine by a Cysteine (Supplementary Fig. S1 ) and is predicted to be deleterious by software such as PolyPhen (with the score of 1.000) and SIFT (with the score of 0.0) (Elinati et al., 2012) . In addition, we found that R298C was predicted to be pathogenic by additional prediction tools. MutPred indicates a deleterious effect with a probability of 0.879. MuStab software predicts that the R298C substitution would decrease protein stability with a confidence of 80.54%. SNPs and GO software indicate also a disease-associated variation with a probability of 0.546. Moreover, this mutation was not found in EVS or ExAC databases (see the Web Resources section for URLs), nor in 35 fertile Tunisian men analyzed in the present study, indicating that R298C is a very rare variant.
In addition, sequence analysis of a third consanguineous patient revealed a new mutation at the junction of exon-intron 16 consisting of 
Table II
Determination of the precise localization of the BPs in 11 unrelated globozoospermic patients based on the presence of 15 nucleotides that are LCR1 or LCR2-specific markers (SM).
LCR SM N8 8 8 8 8 Nuc Position Hg19 GloboT-2 GloboT-17 GloboT-3 GloboT-14 GloboT-5 GloboT-6 GloboT-7 GloboT-11 GloboT-8 GloboT-9 GloboT-18 
963 T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T
G/G G/G G/G G/G G/G G/G G/G G/G G/G SM2.5 C 63 934 955 C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C SM2.6 T 63
936 T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T
SM2.7 G 63 934 867 G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G SM2.8 G 63 934 832 G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G SM2.9 G 63 934 766 G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/GG/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/GG/G G/G G/G G/G G/G G/G G/G G/G G/G G/G G/G SM2.
T 63 934 605 T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T T/T BPs BP1 BP2
For each patient, the BP localization is defined when his genotype shifts from LCR1-to LCR2-SM. Patients GloboT-2 and 17 BPs are located between markers 4 and 5 (BP1). BPs for the other nine patients are located between markers 3 and 4 (BP2 GloboT-2 GloboT-17 GloboT-3 GloboT-14 GloboT-5 GloboT-6 GloboT-7 GloboT-11 GloboT-8 GloboT-9 GloboT-18 (Fig. 3A) . Three different splice-site prediction websites (NetGene2 Server, Alternative Splice Site Predictor and Splice Site Prediction by Neural Network, see the Web Resources section for URLs) predicted that this mutation abolish the donor splicesite of intron 16 and no new sites are predicted to be created. An inappropriate splicing of exon 16 would generate an undefined frame shift disrupting the original reading frame. For four patients with no DPY19L2 mutation identified, we sequenced all 11 exons of SPATA16 and 13 exons of PICK1 and their exon -intron boundaries. However, no mutations were found.
(T/C) 63 934 757 T/T T/T T/T T/T T/T T/T T/T T/T T/T C/C T/T SNP2.19 (G/
Overall, among 18 genetically independent individuals, a molecular defect of DPY19L2 was identified in 77.8% of cases (14 out of 18); 61.1% (11 out of 18) were homozygous for the DPY19L2 deletion, 16.7% (3 out of 18) were homozygous for a point mutation; 2 of them were homozygous for the same point mutation (p.R298C) and 1 patient was homozygous for a newly identified splice-site mutation [c.1579_ 1580+4delAGGTAAinsTCAT] and 22.2% (4 out of 18) were neither mutated for DPY19L2, SPATA16 nor PICK1 (Fig. 3B) .
Discussion
In this present study, we report the molecular analysis of a large cohort of 21 Tunisian globozoospermic patients corresponding to 18 genetically independent individuals. A molecular defect of DPY19L2 was identified in 77.8% of cases, confirming that DPY19L2 alterations are the major cause of globozoospermia.
In our previous study, among 54 patients examined, we identified a frequency of the DPY19L2 defect of 66.7% (36 out of 54), with 46.3% of the patients (25 out of 54) bearing homozygous deletions, 13% (7 out of 54) being compound heterozygous for the deletion and a point mutation (p.R290H, p.T493R, p.K680X, Ex5_6del, p.Q345X and p.S395LfsX7) and 7.4% (4 out of 54) being homozygous for four different point mutations (Ex5_6del, Ex5_7del, c.1218+1G.A and p.R298C) (Elinati et al., 2012) .
When we combine our two studies (Elinati et al., 2012 , and the present study), 69.4% of the 72 analyzed patients had a molecular alteration of DPY19L2 (50 out of 72). In half of the 72 cases (n ¼ 36), complete deletion of DPY19L2 is the cause of globozoospermia; 9.7% of patients (n ¼ 7) were compound heterozygous for the deletion and a point mutation; 9.7% (n ¼ 7) were homozygous for a point mutation and in 30.6% of the cases (n ¼ 22), no identified mutation was found (Fig. 3C) .
When the results of molecular analysis of DPY19L2 from all published studies Elinati et al., 2012; Noveski et al., 2013; Zhu et al., 2013; Ounis et al., 2015) and the present study are combined, 91 out of 123 (74%) patients showed an alteration in DPY19L2. Among them, more than half of the 123 unrelated globozoospermic patients analyzed had a homozygous deletion of DPY19L2 (55.3%, n ¼ 68), 10 Figure 2 Schematic representations of the deletion BPs and hotspot regions as described in three studies (Elinati et al., 2012; Coutton et al., 2013 , and the present study). (A) The nine BPs described in our previous study (Elinati et al., 2012) patients (8.1%) were heterozygous for the deletion, 13 patients (10.6%) were homozygous for a point mutation and for 32 patients (26%), no DPY19L2 mutation was detected (Fig. 3D) . In addition to the new splicesite mutation [c.1579_1580+4delAGGTAAinsTCAT] identified in the present study, 14 different point mutations (Supplementary Table SV) were reported in three previous studies Elinati et al., 2012; Zhu et al., 2013) . Point mutations were either missense/ nonsense/frameshift/splice-site mutations or exon deletions all resulting in a truncated DPY19L2 protein leading to production of roundheaded spermatozoa without an acrosome. So far, DPY19L2 is the first and only protein described to be involved in the attachment of the acrosome to the nuclear envelope (Yassine et al., 2015) . Defects associated with the DPY19L2 gene are known to be the main cause of globozoospermia. It was demonstrated using a Dpy19l2 knockout mouse that the absence of this protein leads to a disruption of the nuclear envelope, resulting in detachment of the acrosome and its loss (Pierre et al., 2012) .
DPY19L2 alterations were mainly identified in the form of total globozoospermia. So far, no genetic causes were associated with the partial form, defined as the presence of both normal and round-headed spermatozoa in the same sperm sample. In our cohort, one patient who was diagnosed with partial globozoospermia (44% round-headed spermatozoa versus 1% normal spermatozoa) and referred to us for molecular analysis had a homozygous DPY19L2 deletion. Sperm analyses for this patient were carried out in a different laboratory and we believe that inter-laboratory variability in scoring is responsible for an overlap of diagnosis and that this patient presents a complete form of globozoospermia.
In order to better characterize the DPY19L2 deletion BPs, we analyzed a 2 kb region on LCR1 and LCR2 in 35 Tunisian fertile men. This allowed us to define 15 LCR-SM (Table II) used to map the BPs, and 20 SNPs (Table III) used to establish patient haplotypes. With reference to the present data, we rechecked and precisely redefined our previously reported BPs (Elinati et al., 2012) . In addition, we showed that some nucleotides described by others (Coutton et al., 2013) as LCR-SM, used to limit their BPs, were in fact found in our study as SNPs; therefore, we also redefine more precisely the localization of these BPs.
Analysis of the 11 globozoospermic patients with a homozygous DPY19L2 deletion led us to identify two BPs located in a small 1 kb region (Fig. 2C ) and a total of eight distinct haplotypes. Elinati et al. (2012) described previously 9 BPs in 27 globozoospermic patients homozygously deleted for DPY19L2. According to our new SM Figure 3 The new DPY19L2 mutation identified and frequencies of DPY19L2 mutation types among different studies. (A) Chromatograms showing the junction part of DPY19L2 exon -intron 16 in a control (wild type) and in a patient who was homozygous for a novel splice-site mutation (c.1579_1580+4 delAGGTAAinsTCAT). The dashed lines indicate the deletions of six nucleotides (AGGTAA) and insertion of four nucleotides (TCAT). The Pie charts show the percentage of DPY19L2 mutation type; (B) among the 18 genetically independent globozoospermic patients analyzed in the present study, 77.8% have a molecular alteration of DPY19L2, with 11 patients (61.1%) homozygous for the deletion of the entire DPY19L2 gene, 3 patients (16.7%) homozygous for a point mutation and 4 were non-mutated patients (22.2%). (C) Considering the present study and our previous one (Elinati et al., 2012) , 69.4% of the fully analyzed patients (n ¼ 72) have a molecular alteration of DPY19L2, 36 out of 72 (50%) patients showed a homozygous deletion for DPY19L2, 7 patients (9.7%) were compound heterozygous for the deletion and a point mutation, 7 patients (9.7%) were homozygous for a point mutation and no mutation was identified for 22 patients (30.6%). (D) Combining all the DPY19L2 studies Elinati et al., 2012; Noveski et al., 2013; Zhu et al., 2013; Ounis et al., 2015 , and the present study); 74% of 123 globozoospermic patients have a DPY19L2 molecular defect, 68 (55.3%) were homozygous for the DPY19L2 deletion, 10 patients (8.1%) were heterozygous for the gene deletion, 13 patients (10.6%) were homozygous for a point mutation and no DPY19L2 mutation was identified for 32 patients (26%).
definitions, BP1-BP6 correspond to only one BP, namely BP2 ( Fig. 2A  and C) . Thus, 24 out of the previous 27 analyzed patients had BP2. Three BPs (BP7, 8 and 9) fell outside of the studied region; consequently, we could not confirm if the nucleotides used to define BP7-9 are LCR-SM or SNPs. However, BP8 and BP9 defined the hotspot 2 region containing the PRDM9 recognition binding motif, which supported its involvement in the DPY19L2 NAHR-driven deletions (Elinati et al., 2012) . Coutton et al. (2013) have described a total of five BPs localized within a 1.2 kb region; three BPs (BP1 -BP3) were identified in 15 DPY19L2 homozygously deleted globozoospermic Tunisian patients and two BPs (BP4-BP5) were identified by sequencing the sperm DNA from three sperm donors of European origin. Comparing the position of the described BPs, we noticed that their LCR-SM (markers 24 and 25), defined by sequencing the same 2 kb regions on LCR1 and LCR2 in 20 controls of North African (10 controls) and European (10 controls) origin and used to limit their BP2, BP3 and BP5, were in fact found in our Tunisian controls as SNPs (SNP7 -SNP6) (Supplementary Table  SIV ). This probably stems from the small cohort of controls analyzed and their origin. Indeed, all of the patients described are Tunisian and they used North African and European controls (Coutton et al., 2013) . This underlines the importance of choosing controls according to the origin of patients under study. According to our new SM definition, this cohort of patients presented, as did the patients that we analyzed, only two BPs and not five. We found that their BP1 correspond to our BP1 and their 'BP2, BP5 and BP3' correspond to our BP2 ( Fig. 2B and C) . Therefore, among their 15 analyzed patients, 7 patients had our BP1 and 8 patients had our BP2.
Overall, from our reanalysis, we found that the most frequent BP among globozoospermic patients carrying the DPY19L2 deletion is BP2 with a total frequency of 77.3% (41/53), while 17% (9/53) had BP1 and 5.7% (3/53) had BPs located outside the region sequenced. In our study, BP2 was shared by 9 out of 11 (81.8%) Tunisian patients compared with 24 out of 27 (88.9%) patients who were recruited from different countries (Algeria, France, Iran, Jordan, Turkey) (Elinati et al., 2012) and 8 out of 15 (53.3%) patients originating from Tunisia but from a different region than our patients) (Coutton et al., 2013) . The fact that the same BP (BP2) is shared by patients from completely different regions and patients from the same country can show different BPs (BP2 or BP1) again excludes the hypothesis of a founder effect, even a recent effect, for the DPY19L2 total gene deletion. In contrast, it supports the advent of recurrent NAHR events linked to the genomic architecture of this locus.
Since the spermatozoa of globozoospermic patients do not present chromosomal abnormalities (Viville et al., 2000; Machev et al., 2005) , a clinical pathway for globozoospermic patients depending on the phenotype was proposed by Kuentz et al. (2013) . In the case of complete or almost complete globozoospermia, patients should be tested for the DPY19L2 homozygous deletion, DPY19L2 point mutations and SPATA16 gene if no mutations in DPY19L2 are found. If a mutation is found and the parents are related, the woman has to be tested to estimate the risk of having an affected male child. In addition to genetic counseling, the clinical management should involve AOA (Kuentz et al., 2013) , as in the case of globozoospermia AOA combined with ICSI has proven to be very efficient in improving fertilization and pregnancy rates (Heindryckx et al., 2005 (Heindryckx et al., , 2008 Taylor et al., 2010; Kuentz et al., 2013) . As DPY19L2 is involved in spermiogenesis, screening for DPY19L2 mutations in patients presenting partial globozoospermia associated with oligozoospermia is not necessary.
Supplementary data
Supplementary data are available at http://molehr.oxfordjournals.org/.
